Nutraceuticals in Patients With Heart Failure: A Systematic Review.
Level 1 - systematic review of randomized trials
Systematic review of comparative clinical studies
PubMed 31704198 · doi:10.1016/j.cardfail.2019.10.014
What was done
Authors conducted a systematic review to evaluate the evidence for nutraceuticals compared to standard care in adults with heart failure to support Australian guideline development. Inclusion prioritized studies with more than 50 patients and at least 6 months of follow-up (smaller and shorter studies were permitted if no larger trials existed). Primary outcomes were mortality/survival, hospitalization, quality of life, and exercise tolerance. Iron was excluded. Forty studies met inclusion criteria.
What was found
The abstract reports no numerical effect sizes, hazard ratios, or confidence intervals. Polyunsaturated fatty acids (omega-3 PUFA) showed the strongest evidence, modestly reducing mortality and cardiovascular hospitalizations in patients predominantly with NYHA class II–III heart failure across ejection fraction ranges. Coenzyme Q10 suggested potential reductions in mortality and hospitalization, but evidence was inconclusive. Studies on nitrate-rich beetroot juice, micronutrient supplementation, hawthorn extract, magnesium, thiamine, vitamin E, vitamin D, L-arginine, L-carnosine, and L-carnitine were underpowered to assess clinical outcomes.
Why it matters
This review establishes that omega-3 PUFAs are the only nutraceutical supported by sufficient clinical evidence to warrant guideline consideration in heart failure. Clinicians should prioritize proven guideline-directed medical therapies over unsupported supplements.
Limits
The abstract provides qualitative conclusions without specific quantitative risk estimates or statistical metrics. Most included nutraceuticals were limited by very small sample sizes (<50 patients) and short follow-up durations (<6 months), leaving clinical outcomes for these agents inadequately evaluated.